ESTRO 2024 - Abstract Book

S5806

RTT - Education, training, advanced practice and role developments

ESTRO 2024

Disease-free survival (primary radical treatment):

No biochemical recurrence

20

Biochemical recurrence

7

Unknown

1

Follow-up:

Median follow-up (months)

28.5 (11-47)

Late Toxicity Incidence/Severity

PROMs data demonstrated low rates of late urinary/bowel toxicities (figure 1).

IPSS scores included mild (n=17, 61%), moderate (n=8, 29%) and severe (n=3, 11%) urinary symptoms. Patients with ‘severe’ scores had lower urinary tract symptoms (LUTS) recorded at baseline.

Bowel toxicity was rarely reported, with 22 (79%) patients experiencing mild/no bowel symptoms. Those who experienced toxicities mostly reported “accidents/spoiling” and “bowel issues affecting mood/social life/relationships/daily life”. Long-term erectile dysfunction (ED) was the most frequently reported issue (figure 1). Most patients (n=19, 68%) experienced ‘severe’ symptoms; of these, 12 were undergoing androgen deprivation therapy (ADT), which may have exacerbated symptoms.